About Surmount Laboratories Limited
Data last updated:
Surmount Laboratories Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 28 March 1996 and has been in existence for over 30 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24230MH1996PLC098511. Its GSTIN is 27AAECS0804K1ZF (Maharashtra). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹6 Cr and a paid-up capital of ₹4.72 Cr. It is led by directors including Minesh Dhirendra Mehta and Dhirendra Maganlal Mehta.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2024, the company reported a revenue of ₹95.33 Cr, a decline of 6% compared to the previous year. For the same year it recorded a net profit of ₹8.42 Cr (net margin 8.8%) and EBITDA of ₹13.33 Cr (EBITDA margin 14%). Revenue has grown at a compounded annual rate (CAGR) of 6% over three years and 8% over five years.
The company has about 19 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Surmount Laboratories. As per MCA filings, the company has open charges of ₹24 Cr and satisfied charges of ₹24.8 Cr on record. The company has 10 deals on record (6 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹2.23 Cr; the latest was in October 2022. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is V S International Private Limited with revenue of ₹96.26 Cr. The company has 4 MSME Form 1 returns on record between 2019 and 2023, listing 91 overdue payments to 47 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website surmountlab.com.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressOffice No. 305 Building No. 3 Wing C – 2 Skyline Wealthspace Premises Chsl, Premier Road Millar Compound Vidyavihar West, Mumbai, Maharashtra, India – 400086
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Surmount Laboratories Limited
The main business activity of Surmount Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Surmount Laboratories Limited FY 2024 filings available
Surmount Laboratories Limited reported revenue of ₹95.33 Cr (down 6% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR) of Surmount Laboratories Limited
Revenue fell 6% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 8%. EBITDA rose 5% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Surmount Laboratories Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | ₹95.33 Cr | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹13.33 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹8.42 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Surmount Laboratories Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 14% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 8.8% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Surmount Laboratories are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Surmount Laboratories Limited
Surmount Laboratories Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| V S International Private Limited | ₹96.26 Cr (FY 2024) | •••• | •••• | 65.0% | •••• | Mumbai, Maharashtra, India |
| XL Laboratories Private Limited | ₹96.06 Cr (FY 2025) | •••• | •••• | 17.0% | •••• | New Delhi, Delhi, India |
| Yeluri Formulations Private Limited | ₹96.05 Cr (FY 2025) | •••• | •••• | -23.0% | •••• | Hyderabad, Telangana, India |
| Zyrex Healthcare Private Limited | ₹95.65 Cr (FY 2024) | •••• | •••• | 364972.0% | •••• | Pune, Maharashtra, India |
| MCW Healthcare Private Limited | ₹95.35 Cr (FY 2024) | •••• | •••• | 16.0% | •••• | Madhya Pradesh, India |
| Surmount Laboratories Limited this company | ₹95.33 Cr (FY 2024) | •••• | •••• | -6.0% | •••• | Mumbai, Maharashtra, India |
| Ang Lifesciences India Limited Listed | ₹94.87 Cr (FY 2025) | •••• | •••• | -35.0% | •••• | Amritsar, Punjab, India |
| Bio-Med Private Limited | ₹94.67 Cr (FY 2025) | •••• | •••• | 19.0% | •••• | Uttar Pradesh, India |
| Impulse Pharma Private Limited | ₹94.61 Cr (FY 2024) | •••• | •••• | 12.0% | •••• | Thane, Maharashtra, India |
| Chiron Behring Vaccines Private Limited | ₹94.53 Cr (FY 2025) | •••• | •••• | 30.0% | •••• | Bhor, Maharashtra, India |
| Daxin Pharmaceuticals Private Limited | ₹93.78 Cr (FY 2025) | •••• | •••• | 40.0% | •••• | New Delhi, Delhi, India |
Peers are the five companies nearest above and the five nearest below Surmount Laboratories by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Board of Directors of Surmount Laboratories Limited
Surmount Laboratories has 3 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Minesh Dhirendra Mehta | Director | 04 Dec 2017 | 8 Years 10 Months | Current |
| Dhirendra Maganlal Mehta Also directs: Surmount Formulations Private Limited | Director | 27 Aug 2020 | 6 Years 1 Months | Current |
| Kavit Dhirendrakumar Mehta Also directs: Surmount Formulations Private Limited | Director | 31 Aug 2022 | 4 Years 1 Months | Current |
Charges & Borrowings of Surmount Laboratories Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Dec 2023 | Others | ₹50 Lakh | Open |
| 04 Oct 2022 | Others | ₹6 Cr | Open |
| 19 Mar 2016 | Others | ₹17.5 Cr | Open |
| 15 Nov 2022 | Others | ₹15 Cr | Satisfied |
| 27 Jun 2013 | Punjab National Bank | ₹7 Cr | Satisfied |
Total charge records: 7 View all charges
Deals & Funding of Surmount Laboratories Limited
Surmount Laboratories Limited has 10 deals on record (6 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹2.23 Cr; the latest was in October 2022.
Deals on record (5 of 10)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Oct 2022 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: 2 individuals |
| Mar 2018 | Funding round | ₹30 Lakh | Investors: an individual |
| Mar 2017 | Rights issue | ₹24 Lakh | Investors: 2 individuals |
| Jun 2014 | Funding round | ₹1 Cr | Investors: 2 individuals |
| Mar 2006 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: Sterfil Laboratories Private Limited , 3 individuals |
Full deal history
All 10 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
MSME Payment Delays by Surmount Laboratories Limited
Surmount Laboratories Limited has 4 MSME Form 1 returns on record between 2019 and 2023, listing 91 overdue payments to 47 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 47)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | •••• | •••• | •••• |
| Ipca Laboratories Limited | •••• | •••• | •••• |
| Sampatti New Life Private Limited | •••• | •••• | •••• |
| Aster Biopharma LLP | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 4 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Surmount Laboratories Limited
Surmount Laboratories operates one associated brand: Surmount Laboratories. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Development, manufacturing, and marketing of pharmaceutical tablets and capsules. | surmountlab.com |
Employees and EPFO Compliance at Surmount Laboratories Limited
Employment history and EPFO contributions of people linked to Surmount Laboratories.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
CIN History of Surmount Laboratories Limited
Surmount Laboratories has one previous CIN (Corporate Identification Number): U24230MH1996PTC098511. The current CIN is U24230MH1996PLC098511, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24230MH1996PLC098511 | Current |
| U24230MH1996PTC098511 | Previous |
Recent Activity on Surmount Laboratories Limited
Surmount Laboratories Limited has 10 board changes on record since 2008: 3 appointments and 7 cessations. The latest: Minesh Dhirendra Mehta ceased to be Director Appointed In Casual Vacancy on 29 Sep 2024.
16 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Surmount Laboratories Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Surmount Laboratories Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Surmount Laboratories Limited
Surmount Laboratories has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAECS0804K1ZF | Maharashtra | Active | 01 Jul 2017 |
| 24AAECS0804K1ZL | Gujarat | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Surmount Laboratories Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Surmount Laboratories Limited
Surmount Laboratories is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 28 March 1996 (30+ years old) and is registered under CIN U24230MH1996PLC098511.
Surmount Laboratories reported revenue of ₹95.33 Cr for FY 2024 (down 6% YoY).
Surmount Laboratories has 3 current directors:
- Minesh Dhirendra Mehta - Director
- Dhirendra Maganlal Mehta - Director
- Kavit Dhirendrakumar Mehta - Director
Surmount Laboratories reported a net profit of ₹8.42 Cr (net margin 8.8%) and EBITDA of ₹13.33 Cr (EBITDA margin 14%) for FY 2024, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Surmount Laboratories is 6% over three years and 8% over five years. In the latest year (FY 2024) revenue fell 6%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Surmount Laboratories is 27AAECS0804K1ZF, registered in Maharashtra. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 24AAECS0804K1ZL (Gujarat).
The CIN (Corporate Identification Number) of Surmount Laboratories is U24230MH1996PLC098511. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Surmount Laboratories was incorporated on 28 March 1996, making it 30+ years old. It is registered with the Registrar of Companies, Mumbai.
Surmount Laboratories has 10 deals on record (6 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹2.23 Cr; the latest was in October 2022.
The peers of Surmount Laboratories by revenue are V S International Private Limited, XL Laboratories Private Limited, Yeluri Formulations Private Limited, Zyrex Healthcare Private Limited, MCW Healthcare Private Limited and 5 more, all in the Pharma industry (Formulations).
Minesh Dhirendra Mehta ceased to be Director Appointed In Casual Vacancy on 29 Sep 2024. Kavit Dhirendrakumar Mehta ceased to be Additional Director on 30 Sep 2022. Kavit Dhirendrakumar Mehta was appointed as Director on 31 Aug 2022. Surmount Laboratories has 10 board changes on record in total.
Surmount Laboratories has 4 MSME Form 1 returns on record between 2019 and 2023, listing 91 overdue payments to 47 micro and small suppliers. The latest return was filed on 23 Apr 2023.